Navigation Links
New Pixantrone Phase III Data to be Presented at the 51st Annual Meeting of the American Society of Hematology

SEATTLE, Dec. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial will present new data on the pixantrone phase III trial in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL) at the 51st Annual Meeting of the American Society of Hematology on Saturday, December 5, 2009 in New Orleans, Louisiana.

The presentation is scheduled for Saturday, December 5, 2009 during the "Lymphoma: Chemotherapy, excluding Pre-Clinical Models" session that will be held from 5:30 p.m-7:30 p.m. Central Time. The presentation, abstract #1677, is titled, "Phase III trial of pixantrone dimaleate compared with other agents as third-line, single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma (EXTEND): Results from the treatment and follow-up periods." The abstract is available at

Separately, CTI will host an investor and analyst meeting providing an overview of the clinical trial results and potential for pixantrone in relapsed/refractory aggressive NHL on December 5, 2009 in New Orleans, Louisiana. Speakers at the event will include John P. Leonard, M.D., Richard T. Silver, Distinguished Professor of Hematology and Medical Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, and Stanley M. Marks, M.D., Director of Clinical Services and Chief Medical Officer, University of Pittsburgh Medical Center Cancer Centers/University of Pittsburgh Cancer Institute, and James A. Bianco, M.D., CEO of CTI. The presentations will begin at 12:45 p.m. Central /10:45 a.m. Pacific /7:45 p.m. Central European Time and conclude at approximately 2:00 p.m. Central/ 12:00 p.m. Pacific/9:30 p.m. Central European Time. The presentations will be webcast live with slides. Webcast and conference call details are as follows:

Saturday, December 5, 2009

Webcast accessible at

Conference Call Numbers

 12:45 p.m. Central/10:45 a.m. Pacific/7:45 p.m. Central European Time:
 1-877-941-2332 (US Participants)
 1-480-629-9722 (International)

 Call-back numbers for post-listening available at 4:30 p.m. Central Time:
 1-800-406-7325 (US Participants)
 1-303-590-3030 (International)
 Passcode: 4186014#

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class. Pixantrone is a fast track designated product which has been accepted for review by the U.S. Food & Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) date of April 23, 2010.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

Sign up for email alerts and get RSS feeds at our Web site,

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL as determined by the FDA, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:                        Investors Contact:
Dan Eramian                           Ed Bell
T: 206.272.4343                       T: 206.272.4345
C: 206.854.1200                       Lindsey Jesch Logan
F: 206.272.4434                       T: 206.272.4347
E:            F: 206.272.4434   E:

SOURCE Cell Therapeutics, Inc.

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone
2. Pixantrone Now Available in Europe on a Named-Patient Basis
3. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
4. Pixantrone Overview in Non-Hodgkins Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference
5. Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
6. Cell Therapeutics Initiates Process to Obtain Marketing Approval for Pixantrone in Europe
7. FDA Accepts to File Cell Therapeutics New Drug Application for Pixantrone
8. Ovation further advances development pipeline with new phase III epilepsy study
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Mannatech Launches Phase One of New Sales and Training Tools
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology: